Inhibition of cell survival and invasion by Tanshinone IIA via FTH1: A key therapeutic target and biomarker in head and neck squamous cell carcinoma

Mao,Wei; Mao,Wei; Mao,Wei; Mao,Wei; Ding,Jian; Ding,Jian; Ding,Jian; Ding,Jian; Li,Yu; Li,Yu; Li,Yu; Li,Yu; Huang,Ruofei; Huang,Ruofei; Huang,Ruofei; Huang,Ruofei; Wang,Baoxin; Wang,Baoxin; Wang,Baoxin; Wang,Baoxin

doi:10.3892/etm.2022.11449

Inhibition of cell survival and invasion by Tanshinone IIA via FTH1: A key therapeutic target and biomarker in head and neck squamous cell carcinoma

Authors:
- Wei Mao
- Jian Ding
- Yu Li
- Ruofei Huang
- Baoxin Wang
View Affiliations

Affiliations: Division of Otolaryngology‑Head and Neck Surgery, Shanghai General Hospital of Jiaotong University, Key Laboratory of Head and Neck, Shanghai 200080, P.R. China
Published online on: June 16, 2022 https://doi.org/10.3892/etm.2022.11449
Article Number: 521
Copyright: © Mao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a worldwide public health problem; its incidence is increasing and it is now the sixth most common cancer type worldwide. As indicated by existing studies, ferroptosis contributes to HNSCC progression and Tanshinone IIA (TanIIA) may exert therapeutic effects via affecting ferroptosis. However, the underlying mechanisms have remained to be clarified. Therefore, the main aim of the present study was to screen and investigate the key genes in regulating ferroptosis of the human hypopharynx squamous carcinoma cell line FaDu and further elucidate the mechanism of action of TanIIA. A list of ferroptosis‑related genes was obtained from the FerrDb database. RNA‑sequencing expression (level 3) profiles and corresponding clinical information (cases, n=502; normal controls, n=44) were downloaded from The Cancer Genome Atlas dataset for HNSCC (https://portal.gdc.com). The limma package in R software was used to study the differentially expressed mRNAs. Adjusted P<0.05 and Log2(fold change) >1 or <‑1 were defined as the threshold for the differential expression of mRNAs. The ClusterProfiler package (version 3.18.0) in R was employed to analyze the Gene Ontology functional terms associated with potential targets and perform a Kyoto Encyclopedia of Genes and Genomes pathway analysis. The R package ggplot2 was used to draw the boxplot and the pheatmap package was used to draw the heatmap. The DEG‑related protein‑protein interaction network was built with the Search Tool for the Retrieval of Interacting Genes and proteins database and then the visualization was performed using Cytoscape. Ferritin heavy chain 1 (FTH1), transferrin (TF) and TF receptor were screened out using a Wayne diagram, which was drawn by the Venn Diagram package in R. Kaplan‑Meier survival analysis and the log‑rank test were used to compare differences in survival between the groups. The receiver operating characteristic (v 0.4) (ROC) curve analysis was used to compare the predictive accuracy of mRNAs. FTH1 was screened out and the expression results were verified using The Human Protein Atlas data. Immunohistochemistry and immunofluorescence were used to localize FTH1 expression in FaDu cells. Furthermore, Cell Counting Kit‑8 and Transwell assays were used to detect the cell survival and invasion ability, respectively. Furthermore, western blot analysis was performed to analyze protein expression. The results of the present study indicated that three validated ferroptosis marker genes were differentially expressed in HNSCC, among which FTH1 was significantly associated with poorer survival. TanIIA was demonstrated to significantly affect FaDu cell survival and invasiveness and markedly attenuate FTH1 expression. To conclude, the ferroptosis gene FTH1 is highly expressed in HNSCC and TanIIA significantly inhibited HNSCC, partially by suppressing FTH1.

View Figures

View References

1	Blanchard P, Landais C, Lacas B, Petit C, Bourhis J and Pignon JP: SP-010: Update of the meta-analysis of chemotherapy in head and neck cancer (MACH-NC). Radiother Oncol. 122(9)2017.
2	Ye J, Jiang X, Dong Z, Hu S and Xiao M: Low-concentration PTX and RSL3 inhibits tumor cell growth synergistically by inducing ferroptosis in mutant p53 hypopharyngeal squamous carcinoma. Cancer Manag Res. 11:9783–9792. 2019.PubMed/NCBI View Article : Google Scholar
3	Lee J, Ji HY, Kim MS and Roh JL: Epigenetic reprogramming of epithelial-mesenchymal transition promotes ferroptosis of head and neck cancer. Redox Biol. 37(101697)2020.PubMed/NCBI View Article : Google Scholar
4	Roh JL, Kim EH, Jang H and Shin D: Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 11:254–262. 2017.PubMed/NCBI View Article : Google Scholar
5	Mou Y, Wang J, Wu J, He D, Zhang C, Duan C and Li B: Ferroptosis, a new form of cell death: Opportunities and challenges in cancer. J Hematol Oncol. 12(34)2019.PubMed/NCBI View Article : Google Scholar
6	Kong N, Chen X, Feng J, Duan T, Liu S, Sun X, Chen P, Pan T, Yan L, Jin T, et al: Baicalin induces ferroptosis in bladder cancer cells by downregulating FTH1. Acta Pharm Sin B. 11:4045–4054. 2021.PubMed/NCBI View Article : Google Scholar
7	Zhu S, Yu Q, Huo C, Li Y, He L, Ran B, Chen J, Li Y and Liu W: Ferroptosis: A novel mechanism of artemisinin and its derivatives in cancer therapy. Curr Med Chem. 28:329–345. 2021.PubMed/NCBI View Article : Google Scholar
8	Guan Z, Chen J, Li X and Dong N: Tanshinone IIA induces ferroptosis in gastric cancer cells through p53-mediated SLC7A11 down-regulation. Biosci Rep. 40(BSR20201807)2020.PubMed/NCBI View Article : Google Scholar
9	Qian J, Cao Y, Zhang J, Li L, Wu J, Wei G, Yu J and Huo J: Tanshinone IIA induces autophagy in colon cancer cells through MEK/ERK/mTOR pathway. Transl Cancer Res. 9:6919–6928. 2020.PubMed/NCBI View Article : Google Scholar
10	Zhao YX, Luo D, Zhang YH, Shen B, Wang BX and Sun ZF: The effect of tanshinone ⅡA potentiates the effects of cisplatin in Fadu cells in vitro through downregulation of survivin. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 31:781–784. 2017.PubMed/NCBI View Article : Google Scholar : (In Chinese).
11	He L, Liu YY, Wang K, Li C, Zhang W, Li ZZ, Huang XZ and Xiong Y: Tanshinone IIA protects human coronary artery endothelial cells from ferroptosis by activating the NRF2 pathway. Biochem Biophys Res Commun. 575:1–7. 2021.PubMed/NCBI View Article : Google Scholar
12	Zhou N and Bao J: FerrDb: A manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database (Oxford). 2020(baaa021)2020.PubMed/NCBI View Article : Google Scholar
13	von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P and Snel B: STRING: A database of predicted functional associations between proteins. Nucleic Acids Res. 31:258–261. 2003.PubMed/NCBI View Article : Google Scholar
14	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003.PubMed/NCBI View Article : Google Scholar
15	Obuchowski NA and Bullen JA: Receiver operating characteristic (ROC) curves: Review of methods with applications in diagnostic medicine. Phys Med Biol. 63(07TR01)2018.PubMed/NCBI View Article : Google Scholar
16	Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, et al: Towards a knowledge-based human protein atlas. Nat Biotechnol. 28:1248–1250. 2010.PubMed/NCBI View Article : Google Scholar
17	Xu LP: Studies on the inhibition of AT#9 on three tumour cells proliferation by cell counting-kit 8. Journal of North Pharmacy. 9:43–44. 2012.(In Chinese).
18	Di Sanzo M, Quaresima B, Biamonte F, Palmieri C and Faniello MC: FTH1 pseudogenes in cancer and cell metabolism. Cells. 9(2554)2020.PubMed/NCBI View Article : Google Scholar
19	Liu C, Guo T, Xu G, Sakai A, Ren S, Fukusumi T, Ando M, Sadat S, Saito Y, Khan Z, et al: Characterization of alternative splicing events in HPV-negative head and neck squamous cell carcinoma identifies an oncogenic DOCK5 variant. Clin Cancer Res. 24:5123–5132. 2018.PubMed/NCBI View Article : Google Scholar
20	Hassannia B, Vandenabeele P and Vanden*Berghe T: Targeting ferroptosis to iron out cancer. Cancer Cell. 35:830–849. 2019.PubMed/NCBI View Article : Google Scholar
21	Zhang K, Ping L, Du T, Liang G, Huang Y, Li Z, Deng R and Tang J: A ferroptosis-related lncRNAs signature predicts prognosis and immune microenvironment for breast cancer. Front Mol Biosci. 8(678877)2021.PubMed/NCBI View Article : Google Scholar
22	Jiang X, Stockwell BR and Conrad M: Ferroptosis: Mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 22:266–282. 2021.PubMed/NCBI View Article : Google Scholar
23	Zhao YY, Lian JX, Lan Z, Zou KL, Wang WM and Yu GT: Ferroptosis promotes anti-tumor immune response by inducing immunogenic exposure in HNSCC. Oral Dis: Nov 12, 2021 (Epub ahead of print).
24	Tang Y, Li C, Zhang YJ and Wu ZH: Ferroptosis-related long non-coding RNA signature predicts the prognosis of head and neck squamous cell carcinoma. Int J Biol Sci. 17:702–711. 2021.PubMed/NCBI View Article : Google Scholar
25	Ni H, Ruan G, Sun C, Yang X, Miao Z, Li J, Chen Y, Qin H, Liu Y, Zhang L, et al: Tanshinone IIA inhibits gastric cancer cell stemness through inducing ferroptosis. Environ Toxicol. 37:192–200. 2022.PubMed/NCBI View Article : Google Scholar
26	Jiang Y, Mao C, Yang R, Yan B, Shi Y, Liu X, Lai W, Liu Y, Wang X, Xiao D, et al: EGLN1/c-Myc induced lymphoid-specific helicase inhibits ferroptosis through lipid metabolic gene expression changes. Theranostics. 7:3293–3305. 2017.PubMed/NCBI View Article : Google Scholar
27	Plays M, Müller S and Rodriguez R: Chemistry and biology of ferritin. Metallomics. 13(mfab021)2021.PubMed/NCBI View Article : Google Scholar
28	Scaramuzzino L, Lucchino V, Scalise S, Conte ML, Zannino C, Sacco A, Biamonte F, Parrotta EI, Costanzo FS and Cuda G: Dissecting the molecular response of human Escs to iron-mediated oxidative stress by genetic silencing of FTH1 gene. Res Sq. 1:1–28. 2021.
29	Lee JH, Jang H, Cho EJ and Youn HD: Ferritin binds and activates p53 under oxidative stress. Biochem Biophys Res Commun. 389:399–404. 2009.PubMed/NCBI View Article : Google Scholar
30	Di Sanzo M, Aversa I, Santamaria G, Gagliardi M, Panebianco M, Biamonte F, Zolea F, Faniello MC, Cuda G and Costanzo F: FTH1P3, a novel H-ferritin pseudogene transcriptionally active, is ubiquitously expressed and regulated during cell differentiation. PLoS One. 11(e0151359)2016.PubMed/NCBI View Article : Google Scholar
31	Mu T, Qin Y, Liu B, He X, Liao Y, Sun J, Qiu J, Li X, Zhong Y and Cai J: In vitro neural differentiation of bone marrow mesenchymal stem cells carrying the FTH1 reporter gene and detection with MRI. Biomed Res Int. 2018(1978602)2018.PubMed/NCBI View Article : Google Scholar
32	Yang L, Sun K, Chu J, Qu Y, Zhao X, Yin H, Ming L, Wan J and He F: Long non-coding RNA FTH1P3 regulated metastasis and invasion of esophageal squamous cell carcinoma through SP1/NF-kB pathway. Biomed Pharmacother. 106:1570–1577. 2018.PubMed/NCBI View Article : Google Scholar
33	Zhang CZ: Long non-coding RNA FTH1P3 facilitates oral squamous cell carcinoma progression by acting as a molecular sponge of miR-224-5p to modulate fizzled 5 expression. Gene. 607:47–55. 2017.PubMed/NCBI View Article : Google Scholar
34	Muhammad JS, Bajbouj K, Shafarin J and Hamad M: Estrogen-induced epigenetic silencing of FTH1 and TFRC genes reduces liver cancer cell growth and survival. Epigenetics. 15:1302–1318. 2020.PubMed/NCBI View Article : Google Scholar
35	Li J, Lama R, Galster SL, Inigo JR, Wu J, Chandra D, Chemler SR and Wang X: Small-molecule MMRi62 induces ferroptosis and inhibits metastasis in pancreatic cancer via degradation of ferritin heavy chain and mutant p53. Mol Cancer Ther. 21:535–455. 2022.PubMed/NCBI View Article : Google Scholar
36	Huang HX, Yang G, Yang Y, Yan J, Tang XY and Pan Q: TFAP2A is a novel regulator that modulates ferroptosis in gallbladder carcinoma cells via the Nrf2 signalling axis. Eur Rev Med Pharmacol Sci. 24:4745–4755. 2020.PubMed/NCBI View Article : Google Scholar
37	Ansari MA, Khan FB, Safdari HA, Almatroudi A, Alzohairy MA, Safdari M, Amirizadeh M, Rehman S, Equbal MJ and Hoque M: Prospective therapeutic potential of Tanshinone IIA: An updated overview. Pharmacol Res. 164(105364)2021.PubMed/NCBI View Article : Google Scholar
38	Zhang Y, Jiang P, Ye M, Kim SH, Jiang C and Lü J: Tanshinones: Sources, pharmacokinetics and anti-cancer activities. Int J Mol Sci. 13:13621–13666. 2012.PubMed/NCBI View Article : Google Scholar
39	Che XH, Park EJ, Zhao YZ, Kim WH and Sohn DH: Tanshinone II A induces apoptosis and S phase cell cycle arrest in activated rat hepatic stellate cells. Basic Clin Pharmacol Toxicol. 106:30–37. 2010.PubMed/NCBI View Article : Google Scholar
40	Won SH, Lee HJ, Jeong SJ, Lee HJ, Lee EO, Jung DB, Shin JM, Kwon TR, Yun SM, Lee MH, et al: Tanshinone IIA induces mitochondria dependent apoptosis in prostate cancer cells in association with an inhibition of phosphoinositide 3-kinase/AKT pathway. Biol Pharm Bull. 33:1828–1834. 2010.PubMed/NCBI View Article : Google Scholar
41	Sui H, Zhao J, Zhou L, Wen H, Deng W, Li C, Ji Q, Liu X, Feng Y, Chai N, et al: Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer. Cancer Lett. 403:86–97. 2017.PubMed/NCBI View Article : Google Scholar
42	Fan Q, Fan GJ, Yang PM and Zhao JY: Effect of tanshinone microemulsion on reversing MDR in human tumor cells. Zhongguo Zhong Yao Za Zhi. 29:1079–1081. 2004.PubMed/NCBI(In Chinese).
43	Xu H, Hao YL, Xu LN, Chen L and Xu FW: Tanshinone sensitized the antitumor effects of irradiation on laryngeal cancer via JNK pathway. Cancer Med. 7:5187–5193. 2018.PubMed/NCBI View Article : Google Scholar
44	Ding L, Wang S, Qu X and Wang J: Tanshinone IIA sensitizes oral squamous cell carcinoma to radiation due to an enhanced autophagy. Environ Toxicol Pharmacol. 46:264–269. 2016.PubMed/NCBI View Article : Google Scholar
45	Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE and Grandis JR: Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 6(92)2020.PubMed/NCBI View Article : Google Scholar
46	Ortiz-Cuaran S, Bouaoud J, Karabajakian A, Fayette J and Saintigny P: Precision medicine approaches to overcome resistance to therapy in head and neck cancers. Front Oncol. 11(614332)2021.PubMed/NCBI View Article : Google Scholar
47	Gougis P, Moreau Bachelard C, Kamal M, Gan HK, Borcoman E, Torossian N, Bièche I and Le*Tourneau C: Clinical development of molecular targeted therapy in head and neck squamous cell carcinoma. JNCI Cancer Spectr. 3(pkz055)2019.PubMed/NCBI View Article : Google Scholar
48	Li X, Si W, Li Z, Tian Y, Liu X, Ye S, Huang Z, Ji Y, Zhao C, Hao X, et al: miR-335 promotes ferroptosis by targeting ferritin heavy chain 1 in in vivo and in vitro models of Parkinson's disease. Int J Mol Med. 47(61)2021.PubMed/NCBI View Article : Google Scholar